Today: 8 June 2026
Browse Category

NASDAQ:ALT 25 November 2025 - 31 January 2026

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune shares traded near $5.03 early Wednesday after closing at the same level Tuesday, with volatility elevated ahead of a key clinical update expected by year-end. The company’s valuation hinges on pemvidutide’s 48-week IMPACT Phase 2b readout for MASH, due in Q4 2025. Leadership changes and wide analyst price targets have added to market uncertainty. The stock jumped 12% intraday on Dec. 12 before retreating.
17 December 2025
·
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune shares traded around $5.29 at 16:50 UTC on Dec. 12, 2025, down 0.9% after a volatile session with heavy volume. The company is preparing for a CEO transition on Jan. 1, 2026, as investors await key pemvidutide Phase 2b data and an FDA meeting. Analyst targets and options activity are adding to the stock’s swings.
12 December 2025
··
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune closed at $5.61 on December 8, 2025, up 7% with heavy trading and high volatility, as short interest reached 30% of float. The company announced CEO Vipin Garg will step down January 1, 2026, with Chairman Jerry Durso taking over ahead of a key MASH trial readout. Analyst targets remain well above current prices despite recent revenue and EPS estimate cuts.
9 December 2025
·
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Altimmune shares traded near $5.10 on November 25, up about 20% over two weeks after Phase 2b data for lead drug pemvidutide was published in The Lancet and highlighted at AASLD. The stock remains down over 50% from its December 2024 high, with investor sentiment tempered by ongoing shareholder lawsuits and a new $400 million shelf registration.
25 November 2025
··

Stock Market Today

  • Ambev Market Outlook: Investor Sentiment Cools
    June 8, 2026, 3:15 AM EDT. The market sentiment for Ambev (ABEV) has recently cooled, reflecting a sober investor stance amid broader economic uncertainties. An experienced analyst with nearly two decades in logistics and a decade in stock investing highlights his diversified holdings across ASEAN and US markets, including Ambev shares. He emphasizes long-term investment balanced with trading strategies, noting no compensation or business ties influencing his perspective. This cautious outlook underscores the need for investors to evaluate fundamentals carefully, amid changing market dynamics and varied sector performances.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop